Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201616 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2370159 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2696782 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL20384849 | 0.94 | KMT2A (0.42) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| Benzonitrile SCHEMBL8546884 | 0.84 | TSHR (0.47) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL31546141 | 0.78 | KMT2A (0.39) | KMT2A | |
| SCHEMBL7108519 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL28971366 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL5852603 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL1109727 | 0.77 | IDO1 (0.47) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235923-A1 | BIOCATALYTIC EPOXIDATION OF VINYLAROMATIC COMPOUNDS | Eidgenössische Technische Hochschule Zürich (CH) | 2002-09-04 | — | — | EP | claimed |
| EP-1106699-A1 | Biocatalytic epoxidation of vinylaromatic compounds | Eidgenössische Technische Hochschule Zürich (CH) | 2001-06-13 | — | — | EP | claimed |
| WO-2001036654-A1 | BIOCATALYTIC EPOXIDATION OF VINYLAROMATIC COMPOUNDS | Eidgenössische Technische Hochschule Zürich (CH) | 2001-05-25 | — | — | WO | claimed |
| US-10376481-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-2887964-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| WO-2001036654-A1 | BIOCATALYTIC EPOXIDATION OF VINYLAROMATIC COMPOUNDS | Eidgenössische Technische Hochschule Zürich (CH) | 2001-05-25 | — | — | WO | disclosed |
| EP-0784698-A4 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | MERCK & CO INC (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5849568-A | Resolution of racemic indene oxide to yield (1S,2R)-indene oxide using Diplodia gossipina | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| CN-1190994-A | Method for quantitative conversion of indene to (1S,2R) -indene oxide and (1S,2R) -indandiol by haloperoxidase bioconversion combined with chemical steps | MERCK & CO INC (US) | 1998-08-19 | — | — | CN | disclosed |
| EP-0784698-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | Merck & Co., Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5605819-A | USING BROMIDE ION AND HYDROGEN PEROXIDE | MERCK & CO., INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996036724-A1 | QUANTITATIVE CONVERSION OF INDENE TO (1S,2R) INDENE OXIDE AND (1S,2R)-INDANDIOL BY COMBINATION OF HALOPEROXIDASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996036724-A1 | QUANTITATIVE CONVERSION OF INDENE TO (1S,2R) INDENE OXIDE AND (1S,2R)-INDANDIOL BY COMBINATION OF HALOPEROXIDASE BIOCONVERSION AND CHEMICAL STEPS | MERCK & CO., INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996012818-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376481-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP2 | KMT2A 3985/4885HTR2A 1156/4885GRIN2D 1953/4885 |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | KMT2A 3985/4885HTR2A 1156/4885GRIN2D 1953/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | KMT2A 3591/4885HTR2A 1230/4885GRIN2D 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.